NCT04293549View on ClinicalTrials.gov

An 8-week Follow-up to Evaluate the Renewal of Corneal Nerves Structure and Function in Patients With Neurotrophic Keratopathy Treated With Recombinant Human Nerve Growth Factor (rhNGF) Eyedrops

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions

Neurotrophic Keratopathy

Interventions

DRUG

Cenegermin, recombinant human Nerve Growth Factor (rhNGF) eyedrops

"rhNGF 20µg/ml (Cenegermin) eyedrops, 1 drop every 2 hours (6 times a day) for 8 weeks.~Patients underwent clinical examination with corneal fluorescein staining, Schirmer I tear test, assessment of corneal sensitivity with Cochet-Bonnet aesthesiometer and morphological examination of the nerves by In Vivo Confocal Microscopy (IVCM) at baseline and after 4 and 8 weeks of treatment"

Trial Locations (1)

66013

Ophtalmology Clinic, G.d'Annunzio University, Chieti

All Listed Sponsors

lead

G. d'Annunzio University

OTHER

NCT04293549 - An 8-week Follow-up to Evaluate the Renewal of Corneal Nerves Structure and Function in Patients With Neurotrophic Keratopathy Treated With Recombinant Human Nerve Growth Factor (rhNGF) Eyedrops | Biotech Hunter | Biotech Hunter